AISight
Manage digitized tissue slides and analyze them in a pathology workspace.
PathAI Funding History
PathAI develops AI algorithms and digital pathology platforms used in diagnostics and biopharma research.
Company Overview
PathAI
Founded 2016 · Boston, Massachusetts, US
Official WebsitePathAI Funding Timeline
Series C
US$165 million
PathAI said the funding would speed product development and support its work with pharmaceutical and diagnostic partners.
Led by D1 Capital, Kaiser Permanente Ventures.
Source · pathai.com ↗Series B
US$60 million
The initial Series B closing preceded strategic investments from LabCorp and other life-sciences companies later that year.
Led by General Atlantic, General Catalyst.
Source · generalatlantic.com ↗Series A
US$11 million
PathAI said the financing would support its deep-learning tools for pathology and help it grow the team.
Led by General Catalyst. Participation included 8VC.
Source · fiercebiotech.com ↗
PathAI Founding Team
PathAI’s founding team combined clinical pathology and computer vision. The company applies those disciplines to the analysis of digitized tissue samples. The founding team included Aditya Khosla and David Klimstra.
- Andrew Beck — CEO. MD-PhD pathologist formerly at Beth Israel Deaconess and Harvard.
PathAI Products
PathAI Company Development
Tissue Analysis Enters the Digital Pathology Workflow
PathAI’s early work applied deep learning to pathology images. It extended that work into a platform for viewing and managing images in clinical and research workflows. Roche’s proposed acquisition puts the combination of workflow software and pathology algorithms at the center of the deal.
PathAI Competitive Landscape
Tissue Slides and Radiology Exams
PathAI builds tools for digital tissue slides used in pathology and biopharma. HOPPR develops infrastructure for medical imaging models. A hospital may evaluate both under an imaging AI strategy, but slide interpretation and radiology model development involve different images, workflows and users.
